The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,296.00
Bid: 12,322.00
Ask: 12,324.00
Change: -108.00 (-0.87%)
Spread: 2.00 (0.016%)
Open: 12,334.00
High: 12,362.00
Low: 12,250.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: Diploma And Victrex Pull Interim Dividends

Mon, 11th May 2020 07:46

(Alliance News) - Stock prices in London are seen opening higher on Monday after the long bank holiday weekend amid tentative steps by the UK government to ease its two-month coronavirus lockdown.

In early company news, industrial firms Diploma and Victrex delivered solid interim results, but both withdrew dividend payments due to uncertainty caused by the health crisis.

IG futures indicate the FTSE 100 index is to open 58.10 points higher at 5,994.10. The blue-chip index closed up 82.22 points, or 1.4% at 5,936.00 on Thursday. The London market was closed on Friday for the VE Day celebrations.

Technical products supplier Diploma said it delivered a robust first-half performance in the face of the Covid-19 pandemic.

For the half-year ended March 31, revenue rose 9% to GBP283.6 million from GBP260.4 million last year, and pretax profit increased 4% to GBP41.6 million from GBP40.1 million.

However, Diploma has decided to suspend payment of an interim dividend.

Looking ahead, Diploma said its outlook for the second half remains uncertain as the global response to Covid-19 pandemic hurts its operations in many of its major markets.

"The group has a resilient and proven business model supported by operating in structurally attractive and diverse sectors and geographies and has a strong balance sheet and liquidity position. The board remains confident in the group's future and expects the group to deliver growth and strong shareholder value creation in the medium term," Diploma said.

Speciality chemicals company Victrex said that, despite global demand for chemicals remaining uncertain, it delivered a solid first half which was in line with expectations.

For the six months to March 31, revenue rose 4% to GBP151.5 million from GBP145.7 million a year before; however, pretax profit edged lower to GBP49.9 million from GBP50.2 million reflecting exceptional items of GBP2.1 million related to the group's China subsidiary investment.

Victrex deferred its interim dividend due to the coronavirus.

It said it made a solid start to the second half with a strong order book.

"We have implemented a range of cash-conservation measures, including deferring our debottlenecking programme and a decision on our interim dividend, and alongside our net cash position and available facilities, our balance sheet remains strong. As previously communicated, with significant macro and end-market uncertainty, we are unable to provide detailed guidance on full-year expectations. We believe the proactive actions we are taking are appropriate to minimise disruption and on a long-term basis, our Polymer & Parts strategy keeps us well placed to deliver our range of medium to long term growth opportunities," Victrex Chief Executive Jakob Sigurdsson said.

AstraZeneca and Daiichi Sankyo Co said that their jointly developed drug Enhertu has been granted breakthrough therapy designation in the US for metastatic gastric cancer.

The pharmaceutical companies said this designation, granted by the US Food & Drug Administration, is designed to accelerate the development and regulatory review of potential new medicines intended to treat a serious condition and address a significant unmet medical need. The FDA's decision was based on data from phase 2 and phase 1 clinical trials, the companies said.

In addition, AstraZeneca said its Lynparza treatment has been approved in the US as first-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer.

UK Prime Minister Boris Johnson on Monday will provide more detailed plans to gradually ease the coronavirus lockdown when the government publishes its official guidance amid widespread calls for clarity.

The prime minister will also face members of Parliament on Monday after offering his "first sketch of a road map" for restarting the economy and social lives in England. He will give a statement to the Commons, with more information expected on a Covid-19 alert system, use of face coverings and the return of professional football.

In a broadcast from Downing Street on Sunday evening, the PM said a phased reopening of schools and non-essential shops in England could potentially begin from June 1 if the transmission can be reduced.

Johnson also said Sunday that Britain would "soon" quarantine air passengers from abroad due to the coronavirus pandemic.

In France, people will from Monday be able to walk outside for the first time in nearly eight weeks without filling in a permit, teachers will start to return to schools, and some shops will reopen. Bars, restaurants, theatres and cinemas will, however, remain closed.

Spaniards outside of urban hotspots such as Madrid and Barcelona - which remain under lockdown - made plans to meet friends and family in bars and restaurants that have outdoor spaces.

The pound was quoted at USD1.2412, up from USD1.2308 at the London equities close on Thursday.

The EU and UK are to take another run at making headway on a post-Brexit trade deal on Monday in a third round of negotiations held by video conference.

The last two rounds yielded little progress, with Brussels lead negotiator Michel Barnier accusing London of refusing to seriously engage with the discussions. Negotiations will continue every day this week until Friday.

The euro was quoted at USD1.0842, up from USD1.0790. Against the yen, the dollar was quoted at JPY106.95, up from JPY106.48.

Brent oil was trading at USD30.60 a barrel Monday morning, lower than USD30.83 late Thursday in London. Gold was quoted at USD1,704.10 an ounce, firm from USD1,700.80.

The Japanese Nikkei 225 index closed up 1.1% on Monday. In China, the Shanghai Composite is down 0.3%, while the Hang Seng index in Hong Kong is up 1.7%.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
20 May 2024 08:24

TOP NEWS: AstraZeneca plans to build manufacturing plant in Singapore

(Alliance News) - AstraZeneca PLC on Monday announced plans for a USD1.5 billion manufacturing facility in Singapore to produce antibody drug conjugates, treatments that deliver "highly potent cancer-killing agents".

Read more
20 May 2024 07:47

LONDON BRIEFING: Keywords would back GBP2.0 billion bid as EQT circles

(Alliance News) - London's FTSE 100 is called to open higher at the start of the week, while the pound climbed and gold hit another record high, with investors hopeful the Federal Reserve could soon cut US interest rates.

Read more
20 May 2024 07:22

AstraZeneca announces $1.5bn Singapore manufacturing facility

(Sharecast News) - AstraZeneca announced plans to construct a $1.5bn manufacturing facility in Singapore on Monday, dedicated to the production of antibody drug conjugates (ADCs).

Read more
17 May 2024 22:25

Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial

May 17 (Reuters) - AstraZeneca owes Pfizer $107.5 million in damages, a Delaware federal jury said on Friday after finding that AstraZeneca's blockbuster lung cancer drug Tagrisso violated its Wyeth unit's patent rights.

Read more
16 May 2024 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Read more
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.